

Date: November 05, 2025

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Subject: Update in respect to our earlier intimation dated July 28, 2025, regarding USFDA Inspection at Havix Group Inc. D/B/A Aavis Pharmaceuticals ("Havix"), Material Subsidiary of the Company

Ref.: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to our earlier intimation dated July 28, 2025, regarding USFDA inspection at Havix Group Inc. D/B/A Aavis Pharmaceuticals ("Havix"), a Material Subsidiary of the Company situated at 9488 Jackson Trail Road, Hoschton, Georgia 30548, USA, we informed that United States Food & Drug Administration ("USFDA") had completed inspection of its manufacturing facility from July 21, 2025 to July 25, 2025 with 3 (Three) minor, 483 observations.

In respect of the same, we would like to further inform that Havix has addressed and resolved the observations and the USFDA has issued Establishment Inspection Report ("EIR") on November 04, 2025.

We request you to take the above information on record.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263